Extracellular vesicle long RNA markers of early‐stage lung adenocarcinoma
Extracellular vesicle long RNA markers of early‐stage lung adenocarcinoma
复制标题
DOI：
10.1002/ijc.34386
复制
发表时间：
2022-11
影响因子：
6.4
通讯作者：
Yanwei Zhang;Wei Liu;Hongdao Zhang;Beibei Sun;Tianxiang Chen;Min-juan Hu;Haisheng Zhou;Yi-Po Cao;B. Han;Ligang Wu
中科院分区：
文献类型：
--
作者：
Yanwei Zhang;Wei Liu;Hongdao Zhang;Beibei Sun;Tianxiang Chen;Min-juan Hu;Haisheng Zhou;Yi-Po Cao;B. Han;Ligang Wu
通过低剂量计算机断层扫描（LDCT）进行肺癌筛查可以提高高危人群的死亡率，特别是预后不良的腺癌病例，尽管高假阳性率限制了其临床应用。我们研究的目的是确定肺腺癌（LUAD）患者和良性对照之间早期肺腺癌（即肿瘤直径1.5）的生物标志物。基于23个基因签名的SVM模型可以区分LUAD患者的EV样本和对照受试者的EV样本，在训练集中具有86.49%的灵敏度、95.00%的特异性和92.31%的准确性，在验证集中具有93.75%的灵敏度、85.71%的特异性和88.24%的准确性。然后确定了一个17基因签名，可以区分AIS患者样本与MIA/IAD患者样本，训练集中的灵敏度为93.33%，特异性为98.00%，准确性为96.25%，验证集中的灵敏度为83.33%，特异性为96.55%，准确性为94.29%。血清中的EvlRNA显示出相当大的诊断价值，用于结合LDCT筛选肿瘤大小<2cm的LUAD患者，潜在地降低假阳性率，同时改善死亡率。
Lung cancer screening by low‐dose computed tomography (LDCT) can improve mortality rates among high‐risk individuals, especially adenocarcinoma cases with characteristically poor prognosis, although high false‐positive rates have limited its clinical application. The objective of our study was to identify biomarkers for early‐stage lung adenocarcinoma (ie, tumor diameter 1.5) were identified between lung adenocarcinoma (LUAD) patients and benign controls. An SVM model based on a 23‐gene signature could distinguish EV samples of LUAD patients from those of control subjects with 86.49% sensitivity, 95.00% specificity and 92.31% accuracy in the training set and 93.75% sensitivity, 85.71% specificity and 88.24% accuracy in the validation set. A 17‐gene signature was then identified that could distinguish AIS patient samples from those of MIA/IAD patients with 93.33% sensitivity, 98.00% specificity, and 96.25% accuracy in the trainingset and 83.33% sensitivity, 96.55% specificity, and 94.29% accuracy in the validation set. EvlRNAs in serum show considerable diagnostic value for screening LUAD patients with tumor sizes <2 cm in conjunction with LDCT, potentially reducing false positive rates while improving mortality rates.